4574 Stock Overview
Manufactures and sells over-the-counter (OTC) medicines in Japan and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Taiko Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥402.00 |
52 Week High | JP¥495.00 |
52 Week Low | JP¥263.00 |
Beta | 0.17 |
11 Month Change | -13.36% |
3 Month Change | 5.24% |
1 Year Change | 18.93% |
33 Year Change | -54.37% |
5 Year Change | -45.45% |
Change since IPO | 43.57% |
Recent News & Updates
Shareholder Returns
4574 | JP Medical Equipment | JP Market | |
---|---|---|---|
7D | -0.7% | 3.8% | 3.7% |
1Y | 18.9% | 17.7% | 12.2% |
Return vs Industry: 4574 exceeded the JP Medical Equipment industry which returned 17.7% over the past year.
Return vs Market: 4574 exceeded the JP Market which returned 12.2% over the past year.
Price Volatility
4574 volatility | |
---|---|
4574 Average Weekly Movement | 6.3% |
Medical Equipment Industry Average Movement | 5.9% |
Market Average Movement | 6.3% |
10% most volatile stocks in JP Market | 10.0% |
10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 4574 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4574's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1946 | 208 | Takashi Shibata | www.seirogan.co.jp |
Taiko Pharmaceutical Co.,Ltd. manufactures and sells over-the-counter (OTC) medicines in Japan and internationally. The company provides OTC medicines for the treatment of loose stools, diarrhea, vomiting, food and water poisoning symptoms, and toothache; and quasi-drugs for regulation of intestinal movements, relieves stomach distention, loose stools, and constipation.
Taiko Pharmaceutical Co.,Ltd. Fundamentals Summary
4574 fundamental statistics | |
---|---|
Market cap | JP¥20.56b |
Earnings (TTM) | -JP¥2.33b |
Revenue (TTM) | JP¥6.49b |
3.1x
P/S Ratio-8.6x
P/E RatioIs 4574 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4574 income statement (TTM) | |
---|---|
Revenue | JP¥6.49b |
Cost of Revenue | JP¥3.29b |
Gross Profit | JP¥3.21b |
Other Expenses | JP¥5.54b |
Earnings | -JP¥2.33b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -46.52 |
Gross Margin | 49.37% |
Net Profit Margin | -35.94% |
Debt/Equity Ratio | 32.2% |
How did 4574 perform over the long term?
See historical performance and comparison